Tang Capital Management LLC Takes Position in COMPASS Pathways plc (NASDAQ:CMPS)

Tang Capital Management LLC acquired a new stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,000,000 shares of the company's stock, valued at approximately $3,780,000. Tang Capital Management LLC owned approximately 1.46% of COMPASS Pathways at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Virtus ETF Advisers LLC lifted its position in shares of COMPASS Pathways by 21.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock valued at $61,000 after acquiring an additional 2,840 shares during the last quarter. Conservest Capital Advisors Inc. lifted its position in shares of COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after acquiring an additional 3,000 shares during the last quarter. Kennedy Capital Management LLC lifted its position in shares of COMPASS Pathways by 22.8% during the 4th quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock valued at $128,000 after acquiring an additional 6,297 shares during the last quarter. Barclays PLC lifted its position in shares of COMPASS Pathways by 2.1% during the 4th quarter. Barclays PLC now owns 419,194 shares of the company's stock valued at $1,585,000 after acquiring an additional 8,718 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in shares of COMPASS Pathways by 15.4% during the 4th quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company's stock valued at $257,000 after acquiring an additional 9,099 shares during the last quarter. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Stock Down 6.1%

Shares of NASDAQ CMPS traded down $0.28 during mid-day trading on Wednesday, reaching $4.34. The company had a trading volume of 1,220,484 shares, compared to its average volume of 829,659. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The company has a market capitalization of $402.96 million, a price-to-earnings ratio of -1.97 and a beta of 2.27. The stock has a fifty day moving average of $3.39 and a two-hundred day moving average of $3.93. COMPASS Pathways plc has a 12-month low of $2.49 and a 12-month high of $8.54.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. As a group, equities research analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald upgraded COMPASS Pathways to a "strong-buy" rating in a research report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price objective on shares of COMPASS Pathways in a research note on Monday, May 12th. Canaccord Genuity Group cut their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. Finally, Stifel Nicolaus began coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $20.20.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.